Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2
Top Cited Papers
- 1 April 2021
- journal article
- letter
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 384 (13), 1273-1277
- https://doi.org/10.1056/nejmc2102131
Abstract
Baden et al.1 report on a phase 3 clinical trial of the mRNA-1273 vaccine against SARS-CoV-2, and they provide information on immediate injection-site reactions, which were observed in 84.2% of the participants after the first dose. The trial also showed that delayed injection-site reactions (defined in that trial as those with an onset on or after day 8) occurred in 244 of the 30,420 participants (0.8%) after the first dose and in 68 participants (0.2%) after the second dose. These reactions included erythema, induration, and tenderness. The reactions typically resolved over the following 4 to 5 days. However, these reactions were not further characterized, and links between reactions after the first dose and those after the second dose were not provided to inform clinical care.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (K01AI125631)
- Massachusetts General Hospital (DOM Transformative Scholar Program)
This publication has 2 references indexed in Scilit:
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineThe New England Journal of Medicine, 2021
- Adverse reactions to vaccines practice parameter 2012 updateJournal of Allergy and Clinical Immunology, 2012